Of all biopsies, 43% overexpressed HER2 (immunohistochemistry score 3+) while literature reports that only 15 to 30% of the newly diagnosed breast tumors overexpress HER2.[38] Also, it is unknown whether our results can be extrapolated to other settings, such as adjuvant breast cancer treatment. This evidence concerns the gene ERBB2 and breast carcinoma.